GRABAR LAW OFFICE INVESTIGATES POTENTIAL SHAREHOLDER DERIVATIVE ACTION ON BEHALF OF INVESTORS OF UNITED THERAPEUTICS CORPORATION (NASDAQ: UTHR)

Pharmaceutical company United Therapeutics Corporation has agreed to pay $210 million to resolve claims that it used a foundation as an illegal conduit to pay the copays of Medicare patients taking UT’s pulmonary arterial hypertension drugs, in violation of the False Claims Act, the Justice Department announced today.

Current United Therapeutics shareholders who have held shares of the Company’s stock since at least 2010 have standing to seek corporate governance reforms, the return of funds back to company coffers and potentially a court approved incentive award if appropriate. $UTHR

If you would like to learn more at no cost to you, fill out the form provided or contact us at jgrabar@grabarlaw.com.

Please enter your name.
Please enter a valid phone number.
Please enter a message.

ATTORNEY ADVERTISING DISCLAIMER: These materials have been prepared by the Grabar Law Office for informational purposes only and does not constitute legal advice. This information is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Online readers should not act upon this information without seeking professional counsel. Prior results referred to in these materials do not guarantee or suggest a similar result in other matters.